Nowtransit INC

Bioscience Health Innovations, Inc. announces the resignation of director Justin Earl and the appointment of CTO Daniel Schmidt to the Board.

BioScience Health Innovations, Inc. completed a 4-for-1 reverse stock split effective September 10, 2025, consolidating its common shares.

BioScience Health Innovations, Inc. (formerly Nowtransit, Inc.) officially changed its name and amended its bylaws to reflect the new corporate identity, effective February 21, 2025.

Nowtransit Inc. has completed a reverse merger with Best Labs, Inc., acquiring a portfolio of health and wellness products and changing its business focus.

Nowtransit Inc. has changed its independent registered public accounting firm from Spiegel Accountancy Corp to Mac Accounting Group & CPAs LLP following a reverse merger with Best 365 Labs, LLC.

BioScience Health Innovations Inc. reported a net loss for the first quarter of 2026, with revenues declining year-over-year, attributed to sales channel adjustments and a rescheduled major order, while advancing its patent-pending product pipeline.

BioScience Health Innovations Inc. reported significant revenue and net income growth for the nine months ended September 30, 2025, driven by strategic initiatives and product development, despite a net loss in the most recent quarter.

BioScience Health Innovations Inc. reported significant revenue and net income growth for Q2 2025, driven by increased sales and marketing efforts, despite ongoing concerns about its ability to continue as a going concern.

BioScience Health Innovations Inc. reports a significant turnaround with net income of $426,798 for Q1 2025, compared to a net loss in the same period last year, driven by increased revenue and strategic initiatives.

Nowtransit Inc. achieved a profitable quarter ending September 30, 2024, driven by increased sales and marketing efforts, despite ongoing concerns about its ability to continue as a going concern.

Nowtransit Inc. reports a profitable second quarter with a net income of $74,222, driven by increased sales and marketing efforts.

BioScience Health Innovations reported 2025 revenue up 208% to $5.69M and net income of $0.64M, detailed capital-raising and uplist plans, and disclosed material internal control weaknesses.

Nowtransit Inc. reports a profitable year end, driven by increased revenue following a reverse merger and a shift to clinically-tested health products.

Nowtransit Inc.'s 2023 annual report details a reverse merger, increased revenue, and a net loss, alongside plans for future growth in the health and wellness market.